ea0029p194 | Bone & Osteoporosis | ICEECE2012
Galesanu C.
, Loghin A.
, Florescu A.
, Lisnic N.
, Aancute P.
, Zaharia V.
Introduction: Bisphosphonates therapy is the standard of care in postmenopausal osteoporosis. In the HORIZON-RFT, annual i.v. Zoledronic acid (ZOL) 5 mg infusion significantly reduced the rate of new fractures by increased bone mineral density (BMD). We proposed to evaluate the effect of ZOL treatment in BMD change in a group of postmenopausal osteoporotic women assessed by DXABMD. We have proposed also to assess the adverse events of this treatment.<p class="abstext...